Fjaellegaard Katrine, Ahmadzai Sina, Porcel José M, Mei Federico, Shaw Jane A, Bodtger Uffe
Pulmonary Research Unit (PLUZ), Department of Respiratory & Internal Medicine, Zealand University Hospital Roskilde and Naestved, Naestved, Denmark.
Nuffield Department of Medicine, University of Oxford, Oxford, Oxfordshire, UK-OX3 7BN, United Kingdom.
Respir Res. 2025 Aug 20;26(1):259. doi: 10.1186/s12931-025-03288-5.
This letter summarizes the current literature on pleural fluid biomarkers that predict treatment response to chemical pleurodesis and indwelling pleural catheters in patients with malignant pleural effusion. We found evidence on pleural fluid biomarkers to be limited to a few small studies, where the biomarkers prognostic value was not tested in separate validation cohorts. Although low pleural fluid LDH, high glucose, and high pH levels are associated with pleurodesis success, no clinically valuable biomarker has been identified. Hence, further research on the inflammatory processes of malignant pleural effusion and during definitive pleural procedures is needed, as well as proper testing of potential biomarkers in separate model derivation and validation cohorts.
这封信总结了目前关于胸腔积液生物标志物的文献，这些生物标志物可预测恶性胸腔积液患者对化学性胸膜固定术和留置胸腔导管治疗的反应。我们发现关于胸腔积液生物标志物的证据仅限于少数小型研究，其中生物标志物的预后价值未在单独的验证队列中进行测试。尽管胸腔积液低乳酸脱氢酶（LDH）、高葡萄糖和高pH水平与胸膜固定术成功相关，但尚未鉴定出具有临床价值的生物标志物。因此，需要对恶性胸腔积液和确定性胸膜手术期间的炎症过程进行进一步研究，以及在单独的模型推导和验证队列中对潜在生物标志物进行适当测试。
